FDA to hold public hearings on CBD in April

Share this post:

Food and Drug Administration (FDA) will hold public hearings on CBD in April, according to statements made by FDA Commissioner Scott Gottlieb, during a recent House Appropriations subcommittee hearing. The purpose of the public hearing will be to start the rule-making process and gather stakeholder input on how the FDA can regulate hemp-derived CBD.

In addition, FDA will form a working group of senior officials and agency experts to advise the Commissioner on regulatory options. Gottlieb affirmed Congress wants a path for regulating food and dietary supplements containing CBD. Gottlieb said, “this is not a straightforward process. There’s not a good proxy for us doing this through regulation.”

The conceptual regulatory framework includes a pharmaceutical path and a path for food products and dietary supplements. Gottlieb specifically mentions FDA approved CBD epilepsy medication, Epidiolex and wanting to maintain a motivation to study CBD for pharmaceutical products by keeping a pharmaceutical regulatory framework.

Although Gottlieb declared his attention to the complexities of regulating CBD, he recently announced his April resignation for personal reasons, almost a year after his appointment as FDA Commissioner.

This information is intended for educational purposes only. No reliance, expressed or implied, may be made on the information on this page or on any of its links. Any persons considering applying for a marijuana business license in the State of Colorado or elsewhere should consult an attorney first. This webpage and its related links do not advocate that anyone violate state or federal law. McAllister Garfield, P.C. is not responsible for any damages incurred as a result of your reliance on the educational information on this page.

Our Offices

Disclaimer: The information on this website is for informational purposes only. This website should not be taken as legal advice. Prior results do not guarantee a similar outcome. This information should not be taken as the formation of a lawyer or attorney client relationship.